A61K 40/4212
Cd22, bl-cam, siglec-2 or sialic acid binding ig-related lectin 2
Official title: {CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2}
A61K40/4212 (Cd22, bl-cam, siglec-2 or sialic acid binding ig-related lectin 2) appears on 94 US grants and 238 published applications in this corpus.
Search patents in A61K- Granted patents
- 94
- Published applications
- 238
- Assignees
- 114
- Inventors
- 515
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 2 |
| 2017 | 0 | 5 |
| 2018 | 4 | 9 |
| 2019 | 2 | 19 |
| 2020 | 7 | 27 |
| 2021 | 14 | 27 |
| 2022 | 6 | 30 |
| 2023 | 7 | 37 |
| 2024 | 15 | 27 |
| 2025 | 25 | 33 |
| 2026 | 13 | 20 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Anti-CD22 single domain antibodies and therapeutic constructs11 Aug 2026US 12,703,744 B2National Research Council of Canada
- Chimeric antigen receptors targeting CD127 and use thereof4 Aug 2026US 12,697,388 B2Memorial Sloan Kettering Cancer Center
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
- Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof6 Aug 2026US 2026/0224700 A1Yale University
- Car molecule, cell or exosome containing same, and use thereof6 Aug 2026US 2026/0226159 A1Wuhan Zhaozhi Biotechnology Co., Ltd
- Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies23 Jul 2026US 2026/0207710 A1Synthorx, Inc.
- Dual car-t cells23 Jul 2026US 2026/0209703 A1Cellectis
Most cited
By later US patents
- CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell27US 10,253,086 B2Novartis AG · 2019
- Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain17US 10,525,083 B2Novartis AG · 2020
- Cell10US 10,098,926 B2Autolus Limited · 2018
- De novo binding domain containing polypeptides and uses thereof10US 10,647,775 B2Arcellx, Inc. · 2020
- De novo binding domain containing polypeptides and uses thereof10US 10,662,248 B2Arcellx, Inc. · 2020